XML 24 R12.htm IDEA: XBRL DOCUMENT v3.20.2
Goodwill and Other Intangible Assets, Net
 9 Months Ended
Oct. 02, 2020
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND OTHER INTANGIBLE ASSETS, NET GOODWILL AND OTHER INTANGIBLE ASSETS, NET
Goodwill
The changes in the carrying amount of goodwill by reportable segment for the nine months ended October 2, 2020 were as follows (in thousands):
MedicalNon- MedicalTotal
December 31, 2019$822,617 $17,000 $839,617 
Foreign currency translation7,347 — 7,347 
Acquisitions and related adjustments (Note 2)4,715 — 4,715 
October 2, 2020$834,679 $17,000 $851,679 
Intangible Assets
Intangible assets at October 2, 2020 and December 31, 2019 were as follows (in thousands):
Gross
Carrying
Amount		Accumulated
Amortization		Net
Carrying
Amount
October 2, 2020
Definite-lived:
Purchased technology and patents$255,475 $(148,792)$106,683 
Customer lists715,589 (153,540)562,049 
Other4,103 (3,704)399 
Total$975,167 $(306,036)$669,131 
Indefinite-lived:
Trademarks and tradenames$90,288 
December 31, 2019
Definite-lived:
Purchased technology and patents$248,264 $(138,435)$109,829 
Customer lists706,852 (131,185)575,667 
Other3,503 (3,503)— 
Total$958,619 $(273,123)$685,496 
Indefinite-lived:
Trademarks and tradenames$90,288 
Throughout the year, the Company has evaluated the effects of the COVID-19 pandemic and its negative impact on the global economy on each of the Company’s reporting units and indefinite-lived intangible assets. Further, the collapse in the demand for oil caused by this unprecedented global health and economic crisis, coupled with oil oversupply, adversely impacted the demand for products in the Company’s Non-Medical reportable segment. In the first quarter of 2020, the Company elected to bypass a qualitative analysis of its Non-Medical reporting unit’s goodwill and performed a quantitative analysis as of April 3, 2020. The fair value of the Non-Medical reporting unit exceeded its carrying amount as of April 3, 2020. No further impairment indicators have been identified since the first quarter of 2020 through October 2, 2020.
When acquiring certain assets, the Company assesses whether the acquired assets are a result of a business combination or a purchase of an asset. In the first quarter of 2020, the Company acquired a set of similar identifiable intangible assets relating to a license to use technology within its Non-Medical segment. The Company paid $3.5 million upon closing, and, based on the completion of certain milestones, paid an additional $0.5 million in the second quarter of 2020 and $0.5 million in the third quarter of 2020. In addition, the Company has capitalized $0.1 million of costs associated with acquiring the license as an intangible asset. The intangible asset of $4.6 million is being amortized over 11 years, the remaining useful life of the patented technology. See Note 13 “Financial Instruments and Fair Value Measurements” for additional information related to the fair value measurement of the contingent consideration.
(5.)    GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Continued)
Aggregate intangible asset amortization expense comprises the following (in thousands):
 Three Months EndedNine Months Ended
 October 2,
2020		September 27,
2019		October 2,
2020		September 27,
2019
Cost of sales$3,219 $3,165 $9,660 $9,622 
Selling, general and administrative expenses7,080 6,617 21,234 19,845 
Total intangible asset amortization expense$10,299 $9,782 $30,894 $29,467 
Estimated future intangible asset amortization expense based on the carrying value as of October 2, 2020 is as follows (in thousands):
Remainder of 2020202120222023 2024After 2024
Amortization Expense$10,193 41,186 40,137 38,720 37,768 501,127